Warren, R. B.; Reich, K.; Simpson, E. L.; Langley, R.; Costanzo, A.; Saeki, H.; Almgren, P.; Vacko, E.; Gooderham, M.; Deleuran, M.; Francisco Silvestre, J.; Weidinger, S.; Blauvelt, A. 3 Years of Tralokinumab Treatment Provides Long-Term Disease Control As Demonstrated by Clinically Meaningful Outcomes in Moderate-to-Severe Atopic Dermatitis. J of Skin 2022, 6, s78.